Please assess the completion status of the following clinical trial:

Trial Title: GA101-miniCHOP Regimen for the Treatment of Elderly Unfit Patients With Diffuse Large B-cell Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically proven CD20 positive Diffuse Large B-cell Lymphoma and Follicular grade III B lymphoma, according to WHO (World Health Organization) classification (local pathologist)~2. Age ≥ 65 years~3. No previous treatment~4. CGA assessment (Comprehensive Geriatric Assessment) performed before starting treatment~5. Unfit patients defined as follows:~   Age \> 80 years with Fit profile, i.e. ADL (Activity of Daily Living) =6 residual functions IADL (Instrumental Activity of Daily Living) =8 residual functions CIRS (Cumulative Illness Rating Scale): no comorbidity of grade 3-4 and \<5 of grade 2 or Age \< 80 with Unfit profile, i.e ADL(Activity of Daily Living) \> 5 residual functions IADL (Instrumental Activity of Daily Living) \> 6 residual functions CIRS (Cumulative Illness Rating Scale): no comorbidity of grade 3-4 and 5-8 co-morbidities of grade 2~6. Ann Arbor Stage I with bulky, II-IV~7. At least one bi-dimensionally measurable lesion defined as \> 1.5 cm in its largest dimension on CT scan~8. ECOG (Eastern Cooperative Oncology Group) performance status of 0, 1, or 2~9. Adequate hematologic function (unless caused by bone marrow infiltrate), defined as follows:~   Hemoglobin ≥ 10 g/dL Absolute neutrophil count ≥ 1.5 x 109/L Platelet count ≥ 100 x 109/L~10. LVEF (Left Ventricular Ejection Fraction) \>50%~11. Ability and willingness to comply with the study protocol procedure~12. Life expectancy \> 6 months~13. Accessibility of patient for treatment and follow up~14. Written informed consent~Exclusion Criteria:~1. History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products~2. Contraindication to any of the individual components of CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone), including prior receipt of anthracyclines~3. History of other malignancies within 5 years prior to study entry except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer~4. Stage I without bulky~5. Patients with transformed lymphoma~6. Prior therapy for DLBCL (Diffuse Large B Cell Lymphoma), with the exception of nodal biopsy or local irradiation~7. Previous exposure to cytotoxic agents~8. Suspect or clinical evidence of CNS (Central Nervous System) involvement by lymphoma~9. HBsAg (Hepatitis B surface antigen), HCV (Hepatitis C Virus) or HIV (Human Immunodeficiency Virus) positivity; isolated HBcAb (Hepatitis B surface antibody) positivity is accepted only with concomitant treatment with Lamivudine~10. AST /ALT (Aspartate Aminotransferase/Alanine Aminotransferase)\> twice upper the normal range; bilirubin \> twice upper the normal range; serum creatinine \> 2.5 mg /dl (unless these abnormalities were related to the lymphoma)~11. Evidence of any severe active acute or chronic infection~12. Concurrent co-morbid medical condition which might exclude administration of full dose chemotherapy

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ga101-miniCHOP (Type: EXPERIMENTAL): 6 courses of GA101-miniCHOP regimen and 2 additional infusions of GA101, every 21 days (for a total of 6 courses of miniCHOP and 10 infusions of GA101).~GA101-miniCHOP regimen:~* Cycle 1 GA101: 1000 mg day 1, day 8 and day 15, iv Cyclophosphamide: 400 mg/mq, day 1, iv Doxorubicin: 25 mg/mq, day 1, iv Vincristine: 1 mg, day 1, iv Prednisone: 40 mg/mq, days 1-5, os~* Cycles 2-6 GA101: 1000 mg day 1, iv Cyclophosphamide: 400 mg/mq, day 1, iv Doxorubicin: 25 mg/mq, day 1, iv Vincristine: 1 mg, day 1, iv Prednisone: 40 mg/mq, days 1-5, os~* Two additional infusions of GA101: 1000 mg day 1, iv, every 21 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).